Form 8-K - Current report:
SEC Accession No. 0001193125-25-277601
Filing Date
2025-11-12
Accepted
2025-11-12 16:12:56
Documents
14
Period of Report
2025-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d814249d8k.htm   iXBRL 8-K 24418
2 EX-99.1 d814249dex991.htm EX-99.1 54632
6 GRAPHIC g814249g1113000012894.jpg GRAPHIC 3098
  Complete submission text file 0001193125-25-277601.txt   211411

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bbot-20251112.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbot-20251112_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbot-20251112_pre.xml EX-101.PRE 11725
16 EXTRACTED XBRL INSTANCE DOCUMENT d814249d8k_htm.xml XML 3794
Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Filer) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41955 | Film No.: 251472858
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)